Business
Apogee Therapeutics to Participate in Upcoming June Conferences
SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences. Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026Fireside Time: 11:40 a.m. ET Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Wednesday, June 10, 2026Fireside Time: 9:20 a.m. ET A live and archived webcast of the fireside chats will be available via the News & Events p
About this update from Apogee Therapeutics, Inc.
[{"type":"image","alt":"Apogee Therapeutics","displaySize":"","headline":null,"caption":"Apogee Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/631e8ba0ee15d045351b6664da548326"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U5TyEiJkPScgY1UNP1ZKtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOA--/https://media.zenfs.com/en/globenewswire.com/631e8ba0ee15d045351b6664da548326","width":300,"height":84},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/U5TyEiJkPScgY1UNP1ZKtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOA--/https://media.zenfs.com/en/globenewswire.com/631e8ba0ee15d045351b6664da548326","width":300,"height":84}},"lazy":false},{"type":"text","content":"SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.","length":199,"tagName":"p"},{"type":"text","content":"Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026Fireside Time: 11:40 a.m. ET","length":113,"tagName":"p"},{"type":"text","content":"Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Wednesday, June 10, 2026Fireside Time: 9:20 a.m. ET","length":123,"tagName":"p"},{"type":"text","content":"A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.","length":159,"tagName":"p"},{"type":"text","content":"About ApogeeApogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achi...